SPR3 is one of at least nine genes which are expressed in sporulating Saccharomyces cerevisiae cells at the time of meiosis I. We show below that strains homozygous for null alleles of SPR3 are capable of normal meiosis and the production of viable ascospores. We have also monitored SPR3 expression in a series of strains that are defective in meiotic development, using an SPR3:lacZ fusion carried on a single copy plasmid. beta-Galactosidase activity occurred at wild-type levels in diploid strains homozygous for mutations in spo13, rad50, rad57 and cdc9, but was greatly reduced in strains carrying cdc8 or spo7 defects. We conclude that SPR3 expression is a valid monitor of early meiotic development, even though the gene is inessential for the sporulation process.

Plasticity of human tumor populations could account for the reason why many tumorigenic human cell lines lose this feature when grown in culture.

The sulfur-regulatory circuit of Neurospora crassa consists of a set of unlinked structural genes which encode sulfur-catabolic enzymes and two major regulatory genes which govern their expression. The positive-acting cys-3 regulatory gene is required to turn on the expression of the sulfur-related enzymes, whereas the other regulatory gene, scon, acts in a negative fashion to repress the synthesis of the same set of enzymes. Expression of the cys-3 regulatory gene was found to be controlled by scon and by sulfur availability. The nucleotide sequence of the cys-3 gene was determined and can be translated to yield a protein of molecular weight 25,892 which displays significant homology with the oncogene protein Fos, yeast GCN4 protein, and sea urchin histone H1. Moreover, the putative cys-3 protein has a well-defined leucine zipper element plus an adjacent charged region which together may make up a DNA-binding site. A cys-3 mutant and a cys-3 temperature-sensitive mutant lead to substitutions of glutamine for basic amino acids within the charged region and thus may alter DNA-binding properties of the cys-3 protein.

No abstract

The United States Food and Drug Administration (FDA) has adopted its accelerated approval regulation as a means of expediting the approval of agents to treat serious or life-threatening illnesses. As of February IS, 2000, I1 oncology products to be used either in the treatment of cancer or in the amelioration of side effects caused by antitumor agents have received accelerated approval.Camptosar3' Injection (irinotecan hydrochloride injection) is an antineoplastic agent that received an accelerated approval on June 14, 1996 for the second-line treatment of metastatic colorectal cancer. Two meetings were held with FDA to discuss the use of data from two Phase I l l studies conducted by RhBne-